GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), a clinical-stage ...

Water and the bad smelling molecule hydrogen sulfide do not seem to have a lot in common at first sight. However, when ...

Key Business Updates BRUKINSA ® (zanubrutinib) is an orally available, small molecule inhibitor of BTK designed to deliver ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...

Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

Cash Position : The Company's cash position as of September 30, 2024, was $41.6 million compared to $9.4 million as of December 31, 2023. This increase is largely due to proceeds from the private ...

Zetagen Therapeutics announces first patients enrolled in phase 2a clinical study of ZetaMet (Zeta-BC-003) for metastatic ...

Biocon is a prominent global biopharmaceutical company driven by innovation, specialising in therapies for chronic conditions ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

“This unique study shows that pimicotinib has the potential to provide a novel oral small molecule therapy option for TGCT patients, representing a key advancement within the emerging class of CSF-1R ...